Table 3 Bivariate analysis of immunosuppressant medication and underlying diseases between patients regarding their medication interruption status prior or after first SARS-CoV2 immunization
Therapy paused (N = 59) n (% proportion) | Therapy continued (N = 148) n (% proportion) | p-value | |
|---|---|---|---|
Underlying diseasea | |||
Organ transplant | 1 (1.7) | 13 (8.8) | 0.0731 |
Inflammatory bowel disease | 10 (16.9) | 28 (18.9) | 0.8441 |
Rheumatic disease | 35 (59.3) | 64 (43.2) | 0.0451 |
Multiple sclerosis | 2 (3.4) | 18 (12.2) | 0.0681 |
Psoriasis | 10 (16.9) | 20 (13.5) | 0.5191 |
Other | 6 (10.2) | 23 (15.5) | 0.3801 |
Immunosuppressantsa | |||
Conv. immunosuppressants | 36 (61.0) | 56 (37.8) | 0.0031 |
Corticoids | 23 (39.0) | 49 (33.1) | 0.4241 |
TNF inhibitor | 13 (22.0) | 26 (17.6) | 0.5551 |
Other biologicals | 12 (20.3) | 27 (18.2) | 0.6991 |
Other | 9 (15.3) | 42 (28.4) | 0.0511 |
Number of taken immunosuppressants | |||
1 | 32 (54.2) | 100 (67.6) | 0.0722 |
2 | 17 (28.8) | 37 (25.0) | |
3 or more | 10 (16.9) | 11 (7.4) | |